

# Nikki Parker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11845745/publications.pdf>

Version: 2024-02-01

14  
papers

1,725  
citations

687363

13  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

2756  
citing authors

#	ARTICLE	IF	CITATIONS
1	Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. <i>Analytical Biochemistry</i> , 2005, 338, 284-293.	2.4	1,054
2	Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue. <i>Cancer Research</i> , 2008, 68, 9839-9844.	0.9	86
3	Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. <i>Journal of Nuclear Medicine</i> , 2004, 45, 857-66.	5.0	82
4	Synthesis and Biological Evaluation of EC72: A New Folate-Targeted Chemotherapeutic. <i>Bioconjugate Chemistry</i> , 2005, 16, 803-811.	3.6	78
5	Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. <i>International Journal of Cancer</i> , 2007, 121, 1585-1592.	5.1	77
6	Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 918-925.	2.5	65
7	In Vivo Structural Activity and Optimization Studies of Folate-Tubulysin Conjugates. <i>Molecular Pharmaceutics</i> , 2009, 6, 1518-1525.	4.6	60
8	Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer. <i>Cancer Research</i> , 2013, 73, 875-884.	0.9	52
9	Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 151.	2.8	43
10	Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 336-343.	2.5	42
11	Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3258-3267.	4.1	33
12	Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F395-F405.	2.7	24
13	Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus. <i>Molecular Medicine</i> , 2015, 21, 584-596.	4.4	22
14	Detecting Functional and Accessible Folate Receptor Expression in Cancer and Polycystic Kidneys. <i>Molecular Pharmaceutics</i> , 2019, 16, 3985-3995.	4.6	7